232 related articles for article (PubMed ID: 23520133)
1. Positive regulation of insulin signaling by neuraminidase 1.
Dridi L; Seyrantepe V; Fougerat A; Pan X; Bonneil E; Thibault P; Moreau A; Mitchell GA; Heveker N; Cairo CW; Issad T; Hinek A; Pshezhetsky AV
Diabetes; 2013 Jul; 62(7):2338-46. PubMed ID: 23520133
[TBL] [Abstract][Full Text] [Related]
2. Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice.
Fougerat A; Pan X; Smutova V; Heveker N; Cairo CW; Issad T; Larrivée B; Medin JA; Pshezhetsky AV
Mol Metab; 2018 Jun; 12():76-88. PubMed ID: 29735266
[TBL] [Abstract][Full Text] [Related]
3. A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.
Alghamdi F; Guo M; Abdulkhalek S; Crawford N; Amith SR; Szewczuk MR
Cell Signal; 2014 Jun; 26(6):1355-68. PubMed ID: 24583283
[TBL] [Abstract][Full Text] [Related]
4. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
5. The sialidase NEU1 directly interacts with the juxtamembranous segment of the cytoplasmic domain of mucin-1 to inhibit downstream PI3K-Akt signaling.
Hyun SW; Imamura A; Ishida H; Piepenbrink KH; Goldblum SE; Lillehoj EP
J Biol Chem; 2021 Nov; 297(5):101337. PubMed ID: 34688655
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
7. Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient.
Penzel R; Uhl J; Kopitz J; Beck M; Otto HF; Cantz M
FEBS Lett; 2001 Jul; 501(2-3):135-8. PubMed ID: 11470272
[TBL] [Abstract][Full Text] [Related]
8. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Seol B; Kim YD; Cho YS
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276
[TBL] [Abstract][Full Text] [Related]
9. Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 crosstalk to induce transactivation of insulin receptor signaling.
Haxho F; Haq S; Szewczuk MR
Cell Signal; 2018 Mar; 43():71-84. PubMed ID: 29277445
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Okada K; Takase R; Hamaoka Y; Honda A; Ikeda A; Hokazono Y; Maeda Y; Hayasaka O; Kotani T; Komatsu M; Shiozaki K
Biochem J; 2020 Aug; 477(15):2841-2857. PubMed ID: 32686823
[TBL] [Abstract][Full Text] [Related]
11. Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Uhl J; Penzel R; Sergi C; Kopitz J; Otto HF; Cantz M
FEBS Lett; 2002 Jun; 521(1-3):19-23. PubMed ID: 12067718
[TBL] [Abstract][Full Text] [Related]
12. Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.
Wang D; Zaitsev S; Taylor G; d'Azzo A; Bonten E
Biochim Biophys Acta; 2009 Apr; 1790(4):275-82. PubMed ID: 19714866
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
14. Short-term, high dose enzyme replacement therapy in sialidosis mice.
Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
[TBL] [Abstract][Full Text] [Related]
15. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide activates microglia via neuraminidase 1 desialylation of Toll-like Receptor 4.
Allendorf DH; Franssen EH; Brown GC
J Neurochem; 2020 Nov; 155(4):403-416. PubMed ID: 32279315
[TBL] [Abstract][Full Text] [Related]
17. In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization.
Bonardi D; Ravasio V; Borsani G; d'Azzo A; Bresciani R; Monti E; Giacopuzzi E
PLoS One; 2014; 9(8):e104229. PubMed ID: 25153125
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.
Hinek A; Bodnaruk TD; Bunda S; Wang Y; Liu K
Am J Pathol; 2008 Oct; 173(4):1042-56. PubMed ID: 18772331
[TBL] [Abstract][Full Text] [Related]
19. Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Seyrantepe V; Landry K; Trudel S; Hassan JA; Morales CR; Pshezhetsky AV
J Biol Chem; 2004 Aug; 279(35):37021-9. PubMed ID: 15213228
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase 1 is a negative regulator of lysosomal exocytosis.
Yogalingam G; Bonten EJ; van de Vlekkert D; Hu H; Moshiach S; Connell SA; d'Azzo A
Dev Cell; 2008 Jul; 15(1):74-86. PubMed ID: 18606142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
